KX2-391 is a first-in-class topical medicine for the treatment of actinic keratosis, and is in late-stage development. Actinic keratosis is a skin condition that is induced through ultraviolet light (sunlight) damage, resulting in patches of thick, scaly, or crusty skin. Left untreated, the lesions have risk of progression to squamous cell carcinoma. Athenex said other drug candidates with KX2-391 as the active ingredient are also being developed for cancer indications.
Athenex (ATNX) has entered into a licensing agreement with China-based Chongqing Jingdong Junzhuo Pharmaceutical to develop and commercialize KX2-391 for the treatment of actinic keratosis and oncology indications in China. The Chinese pharma will include an upfront payment to Athenex of $14.5 million and milestone payments up to $15 million in addition to 15 percent of sales upon commercialization.
Who is Athenex? Formed in 2004, Athenex (dba Kinex) is an innovative oncology company with drug discovery, drug formulation, clinical development, and API/drug product manufacturing facilities in both the U.S. and China. Their mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments.Source: Troy Business News